GOP ad war kicks off in heated battleground state primary: 'We've barely just begun'
Turning Point PAC announced on Tuesday that they're launching a $500,000 media buy across platforms in support of Rep. Andy Biggs on "strategic cable, over-the-top, radio, and direct-to-voter placements" targeting Arizona voters. The ads will begin Tuesday and will air for the next 3.5 weeks. The ads will air on Fox News' local designated market area slots, conservative talk radio and streaming services in addition to targeted digital ads.
"Andy Biggs was the best Senate President Arizona has had in decades and he has been President Trump's most reliable friend in Congress. He is Trump-endorsed, Charlie Kirk endorsed, and Turning Point Action endorsed," Tyler Bowyer, COO of Turning Point Action and Turning Point PAC, said in a statement on Wednesday.
"His campaign momentum is already building at an incredible clip and we've barely just begun. The media buy combined with Biggs's impressive earned media exposure shows how enthusiastic the grassroots is to make Andy Biggs the next governor of Arizona," he added.
Trump Backs Republican Rivals In Arizona Governor's Race After Rep. Biggs Enters Contest: 'I Had A Problem'
The effort's announcement comes as the group held a rally in support of Biggs over the weekend in the Phoenix area.
Read On The Fox News App
"To see a room packed with thousands of Biggs supporters this far out from the primary was truly historic, and it's proof of the grassroots energy that is already gathering behind his campaign," TPUSA founder Charlie Kirk said in a statement. The organization is headquartered in Arizona.
"There isn't a world in which voters will not be aware of Andy Biggs being on the ballot, and the more who find out, the more his double-digit lead over all other competitors will grow. Andy Biggs is ready to bring a President Trump and Ron DeSantis level of leadership and competency to governing Arizona, and Turning Point is proud to get behind his campaign," Kirk continued.
Conservative Group Debuts Major Ad Buy In Key Senators' States As 'Soft Appeal' For Hegseth, Gabbard, Patel
In the primary, Biggs is running against Karrin Taylor Robson, a businesswoman and former Arizona Board of Regents member who sought the nomination in 2022 but lost to Kari Lake. A Taylor Robson ally said that she has been spending that amount of money weekly "talking to voters across all platforms." Her campaign recently touted a "multi-million dollar" ad buy with a commercial touting Trump's endorsement in April.
"I'm proud and honored that President Trump has reaffirmed his endorsement of our campaign," Taylor Robson said in a statement at the time. "It's time that we take our message of America and Arizona First leadership to voters across Arizona. Katie Hobbs has been a disaster and has tried to stand in President Trump's way. As Governor, I will work with President Trump to build a stronger border, a stronger economy, and a stronger and safer Arizona."
The Taylor Robson ally added that Turning Point's decision to spend on advertisements this early affirms that it's a competitive primary race.
Rep. Andy Biggs Eyes Run For Arizona Governor, Says He Understands 'What The State Needs To Thrive'
President Donald Trump said in a Truth Social post that he is backing both Biggs and Taylor Robson for governor, as whoever wins the primary will go up against Gov. Katie Hobbs in what's expected to be a highly competitive general election.
"I like Karrin Taylor Robson of Arizona a lot, and when she asked me to Endorse her, with nobody else running, I Endorsed her, and was happy to do so," Trump said in a Truth Social post in April.
"When Andy Biggs decided to run for Governor, quite unexpectedly, I had a problem — Two fantastic candidates, two terrific people, two wonderful champions, and it is therefore my Great Honor TO GIVE MY COMPLETE AND TOTAL ENDORSEMENT TO BOTH. Either one will never let you down. MAKE AMERICA GREAT AGAIN!" the president added.
The advertising push this early is a testament to the Grand Canyon State's competitiveness, as it was one of the most widely watched swing states in November, which Trump ended up sweeping. Cook Political Report currently ranks the governor's race as a toss-up.Original article source: GOP ad war kicks off in heated battleground state primary: 'We've barely just begun'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 10, Richard Law CFA from Goldman Sachs initiated coverage of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Hold rating and a $36 price target. A doctor and a patient discussing the success of the clinical trial for a new nonpeptide somatostatin receptor agonist. The analyst told investors that Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) near-term value may be considerably influenced by uncertainties, such as the launch performances of paltusotine and Crenessity. He further reasoned that Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) lack of other meaningful pipeline catalysts supports the Neutral rating. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing's disease. While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
a few seconds ago
- Yahoo
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best oversold NASDAQ stocks to buy now. On July 11, BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE), raising the price target to $115 from $100. A biotechnologist in a white lab coat manipulating genes in a laboratory. The analyst told investors in a research note that the new EASI-75 watermark for Biologics in Atopic Dermatitis surpassed expectations, supporting a market-leading profile and painting a positive picture for the company. Apogee Therapeutics Inc. (NASDAQ:APGE) has $681.4 million in cash, cash equivalents, and marketable securities as of March 31. Based on the company's current operating plans, management expects its existing cash, cash equivalents and marketable securities to support its operating expenses into the first quarter of 2028. Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications. While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH)
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best undervalued medical device stocks to buy now. On July 10, Needham analyst Michael Matson maintained a neutral stance on Zimmer Biomet Holdings, Inc. (NYSE:ZBH), giving the stock a Hold rating. The analyst based the rating on the company's recent strategic decision to acquire Monogram Technologies. A team of medical specialists discussing orthopaedic reconstructive surgery plans. The acquisition is valued at around $168 million and aims at boosting the company's robotics and enabling technologies offerings. Although the analyst acknowledged that the acquisition is anticipated to be neutral to earnings per share between 2025 and 2027, he expressed some reservations associated with potential interest from surgeons in a fully automated robotic system. He also stated that the acquisition may potentially bolster Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) standing in the robotics space, especially with the integration of Monogram's AI-navigated knee arthroplasty solutions. Despite this, Matson maintained a cautiously neutral outlook due to his concerns regarding the adoption of fully autonomous systems by surgeons. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) designs, manufactures, and markets orthopedic reconstructive products. It also offers biologics, extremities, sports medicine, dental implants, trauma products, and related surgical products. While we acknowledge the potential of ZBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
